Global Radiopharmaceutical Theranostics and Targeted Alpha Therapies Market Strategic Research Report

The global radiopharmaceutical theranostics and targeted alpha therapies market represents one of the most consequential frontiers in precision oncology, sitting at the convergence of nuclear medicine, molecular imaging, and cancer therapeutics. Valued at approximately USD 8.4 billion in 2024, the market encompasses diagnostic radiopharmaceuticals, therapeutic radionuclide agents, and the companion diagnostic platforms that together define the theranostic paradigm — using the same molecular target for both imaging and treatment. The commercial breakthrough of lutetium-177 PSMA-617 (Pluvicto) in metastatic castration-resistant prostate cancer and actinium-225 and bismuth-213 alpha-emitting platforms have fundamentally reoriented pharmaceutical investment toward this sector, attracting sustained interest from large-cap pharma, specialized biotech, and nuclear medicine infrastructure developers worldwide.

Growth in this market is propelled by three structurally distinct forces. First, the clinical validation of PSMA-targeted therapies has created a replicable theranostic template that is now being applied across a broadening range of tumor types including neuroendocrine tumors, breast cancer (HER2-targeted), and glioblastoma, multiplying addressable patient populations significantly. Second, accelerating regulatory clarity — particularly the FDA's Radioligand Therapy Compendium and parallel frameworks from the EMA — has reduced clinical development uncertainty, encouraging capital allocation from companies that previously avoided the sector's complex supply chain and regulatory requirements. Third, the dosimetric superiority of alpha-emitting isotopes, which deliver cell-killing energy over a path length of 50–80 micrometers compared to beta emitters' millimeter-scale range, is translating into demonstrably improved tumor selectivity in Phase II and Phase III trials, generating meaningful clinical differentiation. The principal restraint on market expansion remains isotope supply scarcity: actinium-225 production capacity, concentrated primarily in a handful of national laboratory reactors and cyclotron networks, is structurally insufficient relative to projected clinical demand through 2028, creating a bottleneck that constrains both commercial launches and clinical trial enrollment.

This report delivers a comprehensive, data-anchored analysis of the global radiopharmaceutical theranostics and targeted alpha therapies market across the 2025–2032 forecast period, with historical context from 2019–2024. It segments the market by radionuclide type, therapeutic modality, and end-use application, and provides granular country-level forecasts for the six most critical national markets. The report is designed specifically for corporate strategy teams evaluating pipeline acquisitions, investment analysts modeling sector valuations, M&A advisors assessing target quality, and procurement managers navigating isotope supply agreements.